SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AMLX

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$26.02-$0.18 (-0.69%)
 
Market cap
$3.35B
Insider Score
Health Score
Analyst consensus
Listed since
Jan 7, 2022
Website
Market Cap$3.35B+75.6%
Revenue (ttm)$0+100.0%
Net Income-$163.19M-9.3%
EPS-$1.42+21.1%
Shares Out128.56M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend DateMar 28, 2018
Volume1,135,931
Open$25.64
Previous Close$26.20
Day's Range$25.52 - $26.40
52-Week Range$10.83 - $41.14
Betan/a
AnalystsBuy
Price Target$49.29(+89.43%)
Earnings DateMar 2, 2027

About AMLX

Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

Address
55 Cambridge Parkway, Cambridge, MA, 02142, US
Market Cap
3.35 billion
Employees
136
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$10.95M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $49.75 (+91.2%)

3 firms rating AMLX in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From AMLX’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-0.69%
5 Days
-13.81%
1 Month
-8.93%
6 Months
+91.61%
1 Year
+75.57%

$AMLX stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AMLX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AMLX's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AMLX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New AMLX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AMLX from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in AMLX

VTIVanguard Morningstar Total Stock Market ETF$86.67M
IWMiShares Russell 2000 ETF$72.44M
VXFVanguard Extended Market ETF$33.60M
IWOiShares Russell 2000 Growth ETF$25.63M
IBBiShares Biotechnology ETF$21.42M
VTWOVanguard Russell 2000 ETF$17.58M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from AMLX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Positive Phase 3 trial results and analyst price target increase outweigh valuation concerns raised in opinion pieces.

Recent Insider Activity

Buys
0
Sells
19
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 25
0255075100Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 20.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 25Sep 29Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SBIOALPS Medical Breakthroughs ETF2.45%
XPHState Street SPDR S&P Pharmaceuticals ETF1.84%
BBCVirtus Biotech Clinical Trials ETF1.61%
PEPTREX Peptide ETF1.59%
IHEiShares U.S. Pharmaceuticals ETF0.66%
FNYFirst Trust Mid Cap Growth AlphaDEX Fund0.62%
MMSCFirst Trust Multi-Manager Small Cap Opportunities ETF0.53%
FSCCFederated Hermes MDT Small Cap Core ETF0.51%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.44%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.37%
FSMLFranklin Small Cap Enhanced ETF0.31%
ESSCEventide Small Cap ETF0.28%

Weight is the stock’s share of each fund’s holdings.